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Isothermal titration calorimetryThe transcription factor hepatocyte nuclear factor 1b (HNF1b) is ubiquitously overexpressed in ovarian
clear cell carcinoma (CCC) and is a potential therapeutic target. To explore potential approaches that
block HNF1b transcription we have identified and characterised extensively the nuclear localisation sig-
nal (NLS) for HNF1b and its interactions with the nuclear protein import receptor, Importin-a. Pull-down
assays demonstrated that the DNA binding domain of HNF1b interacted with a spectrum of Importin-a
isoforms and deletion constructs tagged with eGFP confirmed that the HNF1b 229KKMRRNR235 sequence
was essential for nuclear localisation. We further characterised the interaction between the NLS and
Importin-a using complementary biophysical techniques and have determined the 2.4 Å resolution crys-
tal structure of the HNF1b NLS peptide bound to Importin-a. The functional, biochemical, and structural
characterisation of the nuclear localisation signal present on HNF1b and its interaction with the nuclear
import protein Importin-a provide the basis for the development of compounds targeting transcription
factor HNF1b via its nuclear import pathway.
 2016 MRC Laboratory of Molecular Biology. Published by Elsevier Inc. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction of the HNF1b transcription factor is the most important clinicalOvarian clear cell carcinoma (CCC) accounts for 5–10% of ovar-
ian cancer cases (Anglesio et al., 2011; Kato et al., 2008). Prognosis
for patients with advanced stage or for relapsed disease is poor
because of intrinsic resistance to platinum based chemotherapy
and the lack of targeted therapies available (Tan et al., 2013; Tan
and Kaye, 2007), although Bitler et al. (2015) have recently discov-
ered a way of targeting cancers with ARID1A mutations by target-
ing EZH2 methyltransferase activity. Common mutations in CCC
include loss of function mutations in the chromatin remodeling
gene ARID1A in 46–57% of cases (Jones et al., 2010; Wiegand
et al., 2010), activating mutations in PIK3CA (Kuo et al., 2009) in
33–46% of cases, and loss of PTEN in 20% of cases (Anglesio et al.,
2011; Landen et al., 2008; Tan and Kaye, 2007). Overexpressionimmunohistochemical marker for the disease because it is ubiqui-
tously overexpressed in CCC, both at the mRNA and protein level
(Hirotaka Kajihara et al., 2010; Kato et al., 2006; Tsuchiya et al.,
2003; Yamaguchi et al., 2010). In CCC the HNF1B gene is upregu-
lated by hypomethylation of its CpG island whereas, in high grade
serous ovarian cancer, HNF1b expression is silenced via hyperme-
thylation (Kato et al., 2008; Shen et al., 2013a), suggesting that
HNF1b has a loss of function (tumour suppressor) role in high
grade serous ovarian cancer but a gain of function (oncogenic) role
in CCC (Gounaris et al., 2011; Shen et al., 2013b). This hypothesis is
supported by the observation that nearly half of the overexpressed
genes identified in CCC are downstream targets of HNF1b
(Kobayashi et al., 2009; Yoshida et al., 2009). Evidence that target-
ing HNF1b might have utility was provided by Liu et al. (Liu et al.,
2009) who showed that downregulation of HNF1b increased
cisplatin- and paclitaxel-mediated cytotoxicity.
Transcription factor HNF1b (also known as vHNF1, vAPF, LF-B3
and Tcf2) is expressed in the liver, digestive tract, pancreas and
the kidneys, where it plays a crucial role in early differentiation
(Lu et al., 2007). Sequence-specific DNA binding is mediated by a
bipartite motif that consists of a POU homeodomain (POUH) and a
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1997). HNF1b has 70% sequence homology to HNF1a and both pro-
teins are atypical members of the POU transcription factor family
and bind DNA as both homo- and heterodimers (Bach et al., 1991;
Rey-Campos et al., 1991). Human HNF1b is constructed from three
domains: the dimerization domain, which is further stabilised by
the dimerization cofactor of HNF1 (DcoH), the transactivation
domain, which is involved in binding transcriptional co-activators
[15], and the POU DNA binding domain (HNF1bDBD).
Transcription factors together with histones, DNA polymerase,
RNA polymerase and many other proteins, have specific amino acid
sequences, termed nuclear localisation signals (NLSs), that are
recognised by members of the karyopherin family that facilitate
their nuclear import (reviewed by Lange et al., 2007). Many NLS
sequences are recognised in the cytoplasm by a heterodimeric
transport carrier complex composed of Importin-b (also known as
Karyopherin-b1) and Importin-a (reviewed by Stewart, 2007).
Nuclear pore complexes (NPCs) are the channels through which
macromolecules, such as proteins and RNA, are transported
between the cytoplasm and nucleus (reviewed by Stewart, 2007).
Small molecules and proteins (<40 kDa) can pass through NPCs by
passive diffusion, but larger proteins require carriers to overcome
the NPC physical barrier. The autoinhibitory Importin-b binding
(IBB) domain of Importin-a (Kobe, 1999) binds to Importin-b in
the cytoplasm, enabling classical NLSs (cNLS) to bind to Importin-
a either via a major site, a minor site, or both (Fontes et al., 2000;
Lange et al., 2007). There are two types of cNLS that are recognised
by Importin-a that consist of either a single cluster (monopartite)
or two clusters (bipartite) of positively charged residues, primarily
lysines or arginines, that assume an ordered state once bound by
Importin-a (reviewed by Lange et al., 2007; Marfori et al.,
2011,2012). Monopartite cNLSs are exemplified by the simian virus
40 large T-antigen (SV40) NLS 126PKKKRRV132 (Lange et al., 2007).
The cargo:carrier heterotrimer is then translocated into the nucleus
in an energy dependent manner powered by RanGTPase (reviewed
by Stewart, 2007). In the nucleus, RanGTP then binds Importin-b
leading ultimately to the release of the cargo.
To function, HNF1b needs to be translocated to the cell nucleus
and sowe have investigated and characterised the putative NLS that
has been proposed to lie between the two POU domains of HNF1b.
This putative NLS was identified in domain swapping experiments
and studies of nephrogenesis, inwhich truncatedGFP-HNF1b fusion
constructs retaining the POUH domain showed exclusive nuclear
localisation in transfected HeLa cells (Bohn et al., 2003; Wu et al.,
2004). However, the precise location of the HNF1bNLS has not been
defined. Because of the potential importance of HNF1b as a target in
diseases such as CCC, we have identified and characterised exten-
sively its NLS and its interactions with Importin-a. We demonstrate
that the sequence 229KKMRRNR235 in HNF1bDBD is responsible for
the nuclear import of the protein. Several eGFP-constructs of HNF1b
were generated and Importin-a binding of the HNF1bDBD was
assessed by both pull-down experiments and ITC. We also deter-
mined the crystal structure of the HNF1b NLS peptide bound to
Importin-a. The identification and structural characterisation of
the HNF1b NLS and its interaction with the nuclear import protein
Importin-a provides a basis for the development of inhibitors tar-
geting the nuclear import of transcription factor HNF1b along the
lines suggested by Stelma et al. (2016).2. Materials and methods
2.1. Mammalian cell culture
HEK293T cells were cultivated in Dulbecco’s Modified Eagle
medium (DMEM) (1X) supplemented with 5% foetal bovine serum(FBS) (Invitrogen) and 0.5% penicillin/streptomycin (P/S). CCC cell
lines PEO1, JHOC5, JHOC7, JHOC9, OVISE and SKOV3 cells were
grown in RPMI 1640 medium (1X) supplemented with 10% FBS
and 1% P/S. Normal Ovarian Surface Epithelial (IOSE) cells were
cultivated in NOSE-CM: MCDB 105/medium 199 (1:1 ratio, Sigma
Aldrich), 15% FBS, 10 ng/ml EGF (Invitrogen), 0.5 lg/ml hydrocorti-
sone (Sigma Aldrich), 5 lg/ml insulin (Sigma Aldrich), 34 lg pro-
tein/ml BPE (Invitrogen). All cell lines were maintained at 37 C
in 5% CO2 and were mycoplasma tested on a regular basis
(Biorepository Core, CRUK CI, Cambridge). Cell counts were con-
ducted using a Vi-CELL Cell Viability Analyzer.
2.2. Protein extraction from mammalian cells
Cell pellets were washed with phosphate buffered saline (PBS)
and 200 ll protein lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl,
5 mM EDTA, 0.5% Igepal, to which 2 tablets/100 ml of protease
inhibitor cocktail tablet (Roche)) was added. The mixtures were
incubated on ice for 30 min, lysed by syringing four times using
a 26 G needle, and centrifuged at 14,800g for 10 min at 4 C. Pro-
tein concentrations were measured using the DirectDetect IR spec-
trometer (Merck Millipore) according to the manufacturer’s
instructions.
2.3. Western blotting
Denatured protein extracts were separated using NuPAGE
Novex 4–20% Tris-Glycine gels and transferred to a Millipore
Immobilon FL PVDF membrane (Invitrogen). Primary antibodies
were used as follows: goat anti-HNF1b (sc-7411, polyclonal, Santa
Cruz Biotechnology, 1:1000) and rabbit anti-GAPDH (G9545,
14C10, 1:5000, Cell Signalling Technology). An Odyssey Infrared
Imaging System (Li-Cor) and associated secondary antibodies: don-
key anti-goat (800) (1:15,000) and donkey anti-rabbit (800)
(1:5000) were used to detect material. The expression levels
observed with different cells were evaluated using GraphPad Prism
version 6.0 for Mac, GraphPad Software, La Jolla California USA,
www.graphpad.com. Analysis of variance rejected the null hypoth-
esis that the expression levels were equal (P < 0.002) and Šídák’s
multiple comparison modification of Student’s t-test was used to
evaluate the significance of the levels seen with different cells rel-
ative to that seen with the control HGSOC cell line.
2.4. Confocal microscopy: eGFP imaging and immunofluorescence
assay
For immunofluorescence (IF), cells were fixed with 4%
paraformaldehyde in PBS for 10 min at room temperature, rinsed
in Tris buffered saline (TBS) for 2  5 min and permealized in
TBS-0.5% Triton X-100 for 10 min. Fixed cells were then rinsed in
TBS-0.1% Triton X-100 for 3  3 min and blocked in 10% goat serum
in TBS for 30 min. HNF1b was stained with anti-HNF1b
(SAB1406512, mouse polyclonal, 1:300, Sigma Aldrich) overnight
at 4 C. Cells were washed with TBS-0.1% Triton X-100 (Fisher Sci-
entific) for 3  5 min and the secondary antibody (AlexaFluor 568,
goat anti-mouse IgG (H + L) 1:1000, Invitrogen) was added and
incubated for 60 min diluted in antibody dilution solution consist-
ing of TBS-0.1% Triton X-100, 2% Bovine Serum Albumin (BSA) (Cell
Signaling Technology) and 0.1% sodium azide. All experiments
included an unstained control, a ‘‘secondary only” control, and a
negative control using the PEO1 cell line. Cells transduced with
eGFP-HNF1b, the HNF1b 229KKMRRNR235 deletion mutant, or the
control eGFP constructs, were fixed with 4% paraformaldehyde in
PBS for 10 min at room temperature, then rinsed in TBS for
2  5 min. Nuclei were stained using DAPI (1 lg/ml in TBS) for
10 min. Cells were washed in TBS-0.1% Triton X-100, rinsed in
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cover slips were drained, mounted and sealed using Prolong Gold
(Invitrogen) and glass slides (Thermo Specific). Slides were left to
dry overnight at room temperature in the absence of light and
were then stored at 4 C. Cells were imaged using a Leica tandem
confocal microscope.
2.5. Site directed mutagenesis to generate HNF1b NLS deletion
construct
Lv103 (EX-F0366-Lv103, Genecopoeia) is a lentiviral transfer
vector containing an eGFP-HNF1b fusion coding sequence. Lv105
(EX-EGFP-Lv105, Genecopoeia) only contains the eGFP coding
sequence. The plasmids were confirmed by sequencing (GATC,
Konstanz, Germany) before and after mutagenesis (Lv103 Fw: 50-
CCGACAACCACTACCTGA-30; Rv: 50-ATTGTGGATGAATACTGCC-30
and Lv105 Fw: 50-ATCCACGCTGTTTTGACC-30; Rv: 50-AATACTGC
CATTTGTCTCG-30).
Mutagenesis experiments were conducted using the Q5 site
directed mutagenesis kit (NEB). The 229KKMRRNR235 deletion con-
struct was generated using mutagenesis primers (Fw: 50-TTCAAA
TGGGGGCCGC-30; Rv: 50-GTTGGTGGGCTCAGAGCAG-30). Plasmids
were then transformed in E. coli (One Shot Stbl3TM, Invitrogen)
and streaked on Amp-containing agar plates. Single colonies were
picked and tested for plasmid containing colonies by PCR. Plasmids
were extracted by Plasmid Mini Prep (Qiagen) and quantified
(Qubit).
2.6. Lentivirus production and transduction
The general protocol devised by Cribbs et al. (2013) was used
for lentivirus production. The transfer vectors Lv103, Lv105, the
229KKMRRNR235 deletion mutant, and plasmids pRVS-Rev, pVSV-
G, and p-MDLg-pRRE were verified by restriction digest. For each
transfection sample, 16 lg transfer vector, 10.4 lg pMDL/pRRE,
4 lg pRSV-Rev and 5.6 lg pVSV-G were used. After 24 h, expres-
sion of GFP protein was observed in the GFP control virus HEK293TTable 1
Protein crystallography parameters for DIBB-mImportin-a1 complexed with the
HNF1b NLS peptide.
Data collection statistics
Wavelength (Å) 0.97624
Space group C2221
Unit cell parameters: a, b, c (Å); a,
b, c ()
81.4, 111.4, 129.4; 90.0, 90.0, 90.0
Resolution range (outer shell in
brackets; Å)
129.4–2.40 (2.49–2.40)
Unique reflections 23,388 (2414)
Total observations 173,271 (18,283)
<I/r(I)>: all (outer shell) 10.2 (1.8)
Rp.i.m.: all (outer shell) 0.041 (0.60)
Completeness: all (outer shell) (%) 100 (100)
Multiplicity 7.4
Wilson B-factor 53.7
Refinement statistics
Non-hydrogen atoms 3500
Number of water molecules 53
Bond length deviation from ideal
values (Å)
0.008
Bond angle deviation from ideal
values ()
0.78
Ramachandran favoured/outliers
(%)
98.9/0
All-atom clashscore 1.86
Average protein B factor 67.2
Average water B factor 61.4
Rwork/Rfree (%) 18.4/22.0
MolProbity score (percentile) 0.95 (100)sample. Virus containing supernatant was harvested posttransfec-
tion according to the protocol by Kutner et al. (2009). The number
of transducing units (TU) was determined by flow cytometry anal-
ysis with GFP as the reporter protein. For titration, 1  105 cells per
well were seeded in a 12-well plate and 0.5 ml DMEM with 5% FBS
added. Virus of respective concentration was pipetted over the
HEK293T cells. Duplicate virus dilutions of 1:500, 1:1000, 1:2000,
1:5000 were added. An untreated control was included. The med-
ium was changed 24 h posttransfection. 72 h posttransfection cells
were harvested by trypsinization. Cells were collected by centrifu-
gation at 500g for 5 min at room temperature. The supernatant was
discarded and cell pellets were resuspended in PBS. A green fluo-
rescent protein propidium iodide (GFP PI) based assay for flow
cytometric measurement of transfection efficiency and cell viabil-
ity was performed (LSR-II machine). The titre was calculated from
dilutions that gave 1–40% GFP-positivity and averaged subse-
quently using the following formula:
Titre
TU
ml
 
¼ðfrequency of GFP-positive cellsÞno:cells plateddilution factor
volume of inoculum
where, frequency of GFP-positive cells is the percentage of cells that
are positive for GFP divided by 100 (acceptable range: 0.01–0.40),
dilution factor is the dilution of the virus stock used and volume
of inoculum is the total volume transduced. The titre was calculated
to be 2:26 108 TUml.
For transduction of the PEO1 cell line, 1  106 cells per well
were seeded in a 12-well plate to which 0.5 ml of the respective
medium was added. Virus was added so that the desired multiplic-
ity of infection (MOI) was obtained. Polybrene 0.5–10 lg/ml was
added to increase transduction efficiency. Transduction efficiencies
were determined by flow cytometry analysis using an LSR-II
machine. For selection of transduced PEO1 lines, a puromycin kill
curve was constructed (data not shown) to determine the optimum
concentration of puromycin required to kill all untransduced cells
while minimising toxicity effects in transduced cells. A puromycinFig. 1. (A) HNF1b protein expression levels in CCC cell lines OVISE, JHOC5, JHOC7,
JHOC9, SKOV3 and a negative control HGSOC cell line, PEO1; (B) Data is the mean
(n = 3, three biological replicates) and SEM. Expression levels were normalised to
the housekeeping protein GAPDH. The expression levels observed with JHOC5
(P < 0.005, ⁄⁄⁄) and OVISE (P < 0.05, ⁄) cells were significantly higher than PEO1.
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experiments.
2.7. Quick change mutagenesis to generate GST-tagged HNF1bDBD and
mImportin a1 mutants
The cloning of the DNA binding domain of HNF1b into the
pGEX-TEV plasmid was conducted as described by Lu et al.
(2006). The plasmid was confirmed by sequencing by Source Bio-
science (Cambridge, UK) using PGEX5 and PGEX3 primers (Source
Bioscience).
2.8. Protein expression in bacterial cells and purification
All proteins were expressed in E. coli BL21 (DE3) CodonPlus-RIL
cells using IPTG induction over 18 h at 18 C. The cells were har-
vested by centrifugation and resuspended in 50 mM Tris/HCl
pH 8.0, 500 mM NaCl, 5 mM DTT for GST-tagged constructs or
50 mM Tris/HCl pH 8.0, 500 mM NaCl, 20 mM Imidazole pH 8.0
for His6-tagged proteins. The E. coli were lysed by two passes
through an Emulsiflex C3 system (AVESTIN) running at a pressure
of 15,000 psi and the lysates clarified by centrifugation at 48,000g.
Either Ni-NTA agarose resin (QIAGEN) or glutathione Sepharose 4B
resin (GE Healthcare) was added to the clarified lysate containing
His6-tagged proteins or GST-tagged proteins. The resin was pooled
and packed into a gravity filtration column and washed extensively
with their respective lysis buffers. 1 mg of TEV protease (purifiedFig. 2. eGFP imaging of PEO1 transduced lines with (a) eGFP-HNF1b (Lv103) showed p
(Lv105) alone (b) showed both nuclear and cytoplasmic localisation. In cells transduce
Mutant 8) the eGFP signal was mislocalized to the cytoplasm. The scale bar represents 80
60 objectives.in-house) was added to the washed resin and incubated for 18 h
at 4 C. The tag-free protein of interest was then collected from
the flow-through and subjected to the next purification step.
HNF1bDBD was purified further by heparin affinity chromatography
using a HiTrap Heparin HP column (GE Healthcare Life Sciences).
HNF1bDBD was eluted from the column using a 0.1–1 M NaCl gradi-
ent. All proteins were purified to homogeneity by size exclusion
chromatography using a HiLoadTM 26/60 SuperdexTM 75 prep grade
column (GE Healthcare) pre-equilibrated in 20 mM HEPES buffer
pH 8.0, 200 mM NaCl. Fractions containing pure and homogenous
proteins identified by SDS-PAGE analysis were pooled and concen-
trated using an Amicon Ultra 15 centrifugation filtration unit. Pro-
tein concentrations were measured using a Nanodrop (Thermo)
microspectrophotometer and small aliquots of the protein were
flash frozen in liquid nitrogen and stored at 80 C until required.
2.9. GST pull-downs
After bacterial cell lysis, cell pellets expressing the two proteins
of interest were mixed and pull-down experiments were con-
ducted as described above for glutathione affinity chromatography
and were visualised by SDS-page analysis.
2.10. Isothermal calorimetry
The Kd of mImportin-a1 with the HNF1b NLS peptide
(Ac-TNKKMRRNRFK-NH2, purchased from Insight Biotechnology)rimarily nuclear localisation of the GFP signal, whereas cells transduced with eGFP
d with eGFP-HNF1b (Lv103) in which the seven-residue NLS had been deleted (c,
lm. Images were taken on a Leica tandem confocal microscope using 20, 40 and
M.M. Wiedmann et al. / Journal of Structural Biology 195 (2016) 273–281 277was determined by isothermal titration calorimetry (ITC) using a
MicroCalTM iTC200 (GE Healthcare Life Sciences). The protein and
peptide samples were made up in the identical buffer (20 mM
Hepes pH 8, 200 mM NaCl). 350 ll of protein sample (0.02 mM)
and 200 ll of ligand (0.2 mM) were prepared for each experiment.
Sample concentrations were confirmed by amino acid analysis
(PNAC Facility, Biochemistry Department, Cambridge University).
All experiments were conducted at 25 C. The data was analysed
using the OriginTM Software (MicroCal) using a one site binding
model.2.11. Protein crystallography
Diffraction quality crystals of the Importin-a1DIBB:HNF1bNLS
complex were obtained by sitting drop vapour diffusion where
200 nl of 10% PEG 8 K, 0.09 M NPS, 20% ethylene glycol, 0.1 M
Buffer 1 (Morpheus Screen, Molecular Dimensions) was mixed
with 200 nl of Importin-a1DIBB:HNF1bNLS. The Importin-a1DIBB:
HNF1bNLS complex was produced by mixing Importin-a1DIBB and
HNF1bNLS peptide (Ac-TNKKMRRMRFK-NH2, Insight Biotechnol-
ogy) at a 1:1.1 M ratio and a concentration of 6.7 mg/ml.Fig. 3. (A) Stable complex formation between DIBB mouse Importin-a1 (50 kDa)
and HNF1b (27 kDa) during size exclusion chromatography. Fractions were
analysed by Coomassie stained SDS-PAGE (⁄ marks the peak for the complex); (B)
GST pull-down with liberated HNF1b showing pull-downs using different DIBB
mouse Importin-a isoforms (red ⁄).Crystals were cryoprotected in the mother liquor supplemented
with 20% glycerol and cooled by plunging into liquid nitrogen. X-
ray diffraction data were collected on beamline I03 at the Diamond
Light Source (Didcot, UK). Reflections were indexed and integrated
using DIALS as implemented in Xia2 (Kabsch, 2010) and then scaled
and merged in AIMLESS, ensuring a completeness of >98% in the
outermost shell while maintaining CC1/2 > 0.3 (Evans and
Murshudov, 2013). The structure was solved by molecular replace-
ment using Phaser with the structure of DIBB-mImportin-a1
complexed with a minor site small molecule inhibitor (PDB ID:
4U54 – Holvey et al., 2015) to avoid introducing model bias into
the NLS binding sites. Iterative cycles of rebuilding using COOT
(Emsley et al., 2010) and refinement using PHENIX (Adams et al.,
2010) were used to generate the final model (Table 1) that had
an R-factor of 18.4% (R-free = 22.0%) and a MolProbity (Chen
et al., 2010) score of 0.95 (100th percentile).Fig. 4. (A) ITC titration for the binding of the HNF1b NLS peptide to DIBB
mImportin-a1. Fitting the data (with v2/DoF = 2.9  104) gave a Kd of 13.6 ± 1.5 nM
for 0.94 ± 0.13 sites, DH = 7.2 ± 1.6 kcal/mol, DS = 1.7 cal/mol/deg. (B) In pull-
down assays, GST-HNF1b bound only the E mutant of DIBB Xenopus Importin-a1
(that impairs NLS binding at the minor site) Mr 50 kD, but not the D mutant (that
impairs binding at the major site) or ED double mutant (see Giesecke and Stewart,
2010).
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3.1. HNF1b is overexpressed in CCC cell lines
HNF1b protein expression in different CCC cell lines was deter-
mined by Western blotting (Fig. 1) using the HGSOC cell line PEO1
(which does not express HNF1b) as a negative control. The CCC
lines OVISE, JHOC5, JHOC7, JHOC9 and SKOV3 cell lines were used
as models of CCC that overexpress HNF1b. Several splice variants of
HNF1b are known to contain different isoforms of the C-terminal
domain that is responsible for activation of transcription. These
isoforms act as transdominant repressors (Bach and Yaniv, 1993).
Only the 61 kDa isoform of HNF1b was detected in our CCC cell
lines (Fig. 1) (Bach and Yaniv, 1993; Tsuchiya et al., 2003). HNF1b
expression levels varied considerably between these cell lines.
Analysis of variance of the data in Fig. 1 rejected the null hypoth-
esis that the expression levels were equal (P < 0.002) and the
higher level seen in JHOC7 compared with PEO1 cells was signifi-
cant at the 0.5% level (using Sidak’s modification for multiple com-
parisons), consistent with hypomethylation of the HNF1b CpG
island (Kato et al., 2008, 2007).3.2. Identification of the HNF1b nuclear localisation signal
To confirm the identity of the NLS, the PEO1 cell line was trans-
duced with lentiviruses Lv103 (eGFP-HNF1b), Lv105 (eGFP) and
the 229KKMRRNR235 deletion mutant. In cells transduced with
eGFP-HNF1b, the fusion protein (eGFP-HNF1b (Lv103) – Fig. 2AFig. 5. (A) Overview of the 2.4 Å crystal structure of the DIBB mouse Importin-a1:HNF1b
the major site (blue) and another in the minor site (yellow). Each ARM repeat of mous
density map around NLS peptide in major and minor binding sites on mouse Importin-(Mutant 8)) was primarily nuclear, whereas cells transduced with
Lv105 (eGFP) showed nuclear and cytoplasmic localisation of the
eGFP protein (eGFP (Lv105) – Fig. 2B). Deletion of the seven-
residue 229KKMRRNR235 NLS sequence in HNF1b resulted in its
becoming mislocalized to the cytoplasm (Mutant 8, Fig. 2C), con-
firming the importance of this sequence for the nuclear import of
HNF1b. HNF1a has an analogous KKGRRN sequence that differs
only at residue 231, where Met is changed to Gly (Wu et al.,
2004) and which probably also functions in a similar manner.
Interestingly, all transduced cells (that were selected using opti-
mised puromycin concentrations) were apoptotic within 24 h.
We speculate that re-expression of a transcription factor that is
epigenetically silenced in HGSOC cell line PEO1 (Shen et al.,
2013a) may have a negative effect on proliferation, but further
work is necessary to determine the effects of re-expression.3.3. HNF1bDBD binds primarily to the major site on Importin-a
Because the sequence of the HNF1b NLS is similar to that of clas-
sical monopartite NLSs (Lange et al., 2007; Marfori et al.,
2011,2012), HNF1b is likely to be imported by Importin-a and to
interact with its major NLS-binding site rather than being imported
by direct binding to Karyopherin-b (Fontes et al., 2000). To test
whether HNF1b and mImportin-a formed a complex, recombi-
nantly expressed and purified HNF1bDBD and mImportin-a1 in
which the IBB domain had been deleted (DIBB-mImportin-a1)
weremixed together and analysed by gel filtration chromatography
(Fig. 3A), in which DIBB-mImportin-a1 and HNF1bDBD co-eluted asNLS complex. Two copies of the NLS peptide were observed where one was bound in
e Importin-a1 has been labelled with alternating colours. (B) Final 2Fo-Fc electron
a1 contoured at 1r.
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SDS-PAGE analysis. To establish whether HNF1b interacts with
other Importin-a isoforms, pull-down experiments using different
DIBB-mImportin-a1 isoforms were performed (Fig. 3B). Crude
extracts of GST-tagged HNF1b and DIBB-mImportin-a1 isoforms
were mixed, then bound to glutathione resin, washed, and eluted
by cleaving between GST and HNF1bDBD using TEV protease. Both
HNF1bDBD and DIBB-mImportin-a1 were released, confirming that
they were interacting (Fig. 3B). HNF1b interacted more
strongly with DIBB-mImportin-a5 and less strongly with DIBB-
mImportin-a3, -a4 and -a7 isoforms. The Kd for the interaction of
DIBB-mImportin-a1 with the HNF1b NLS peptide was determined
by isothermal calorimetry (ITC) (Fig. 4A) to be 13.6 ± 1.5 nM which
was in the range commonly observed (Hodel et al., 2006). In sum-
mary, HNF1b binds at least two DIBB-mImportin-a isoforms
strongly and some other isoforms more weakly.
Three different Xenopus Importin-a1 (xImportin-a1) mutants
(Giesecke and Stewart, 2010) were used to define where the HNF1b
NLS bound on Importin-a (Fig. 4B). These mutants contained point
mutations that prevent binding via the major (D), minor (E), or
both (ED) sites and also have the IBB domain removed to prevent
auto-inhibition (Kobe, 1999). HNF1bDBD bound to the E mutant
but not the D or ED mutant ofDIBB-xImportin-a1 (Fig. 4B), indicat-
ing that HNF1b binds primarily via the major site, consistent with
its similarity to the SV40 NLS (Lange et al., 2007; Marfori et al.,
2011,2012).Fig. 6. Schematic illustration of the interactions of the HNF1bNLS peptid3.4. Structural characterisation of the interaction of mImportin-a1
with the HNF1b NLS
To complement the functional and biochemical data, we also
determined the 2.4 Å resolution crystal structure of the HNF1b
NLS peptide bound to DIBB-mImportin-a1 (Fig. 5A). After initial
rounds of refinement, strong difference density, corresponding to
the peptide was found in both the major NLS-binding site on
Importin-a1 together with weaker density at the minor site
(Fig. 5B and C, respectively).
At the major site, the HNF1b NLS peptide backbone interacted
with Importin-a1 via a set of conserved Asn residues on the import
protein by H-bonding (Fig. 6A). The NLS residues are convention-
ally assigned to positions P1-P5 (Fig. 6). Key residues on
Importin-a involved for the interaction with the NLS were Asn-
235, 188 and 146, the latter two of which are involved in bidentate
H-bonding with the NLS peptide backbone at P3 and P5. The ali-
phatic portions of the NLS peptide side chains were located in shal-
low pockets along the surface of Importin-a, but, as evident from
Fig. 6A, the P2 residue, Lys230, forms many critical interactions,
mostly by forming salt bridges with negatively charged residues
on Importin-a. There were three interactions of the protonated
nitrogen on the P2 lysine side chain with Asp192, Gly150 and
Thr155. Residue P5 interacted with the side-chain of Gln181. Fur-
thermore, NLS residues P3 and P5 were stacked against the aro-
matic indole rings of Trp231, Trp184 and Trp142 on Importin-a,e in the major (A) and minor (B) sites on DIBB mouse Importin-a1.
280 M.M. Wiedmann et al. / Journal of Structural Biology 195 (2016) 273–281with the latter two being aligned in parallel. Interestingly, residues
231MRRNR235 also form part of the HNF1b DNA binding site identi-
fied by crystallography (Lu et al., 2007; PDB accession code 2H8R),
which is analogous to the overlap between NLS and DNA binding
seen in the androgen receptor (Cutress et al., 2008; PDB accession
code 3BTR).
Weaker difference density was also observed in the minor NLS-
binding site on Importin-a1 and displayed a partly a-helical con-
formation (Fig. 6B). Several atypical, minor site selective NLSs have
previously been characterised structurally to adopt a similar topol-
ogy (Chang et al., 2013; Nakada et al., 2015). Our pull-down exper-
iments with xImportin-a protein mutants have demonstrated that
the interaction was primarily via the major site on Importin-a and
so the presence of the peptide density in the minor site was prob-
ably due to the high protein concentration used to produce the
crystals together with the peptide having additional degrees of
freedom that may not present in the context of the intact HNF1b
protein. NLS residues Lys229 (P1), Met231 (P3) and Arg233 (P5)
bound into apolar and shallow pockets consisting of aromatic tryp-
tophan residues (Trp231, Trp184 and Trp142) stacked in parallel.
Identifying the HNF1b NLS and its mode of interaction with
Importin-a provides a basis of the design of therapeutic agents
along the lines being investigated for other nuclear factors that
aim to impair nuclear import to which cancer cells are often more
sensitive (reviewed by Stelma et al., 2016). For example, Lin et al.
(1995) developed a 41-residue synthetic peptide (that contained
the NLS of transcription factor NF-jB together with a cSN50 cell
membrane permeable motif) that inhibited the nuclear transloca-
tion of NF-jB and attenuated gene transcription in intact cells,
but was not cytotoxic within the concentration range of the exper-
iments (Torgerson et al. 1998).
In summary, we have confirmed, using eGFP-tagged deletion
constructs, that in the HNF1b transcription factor that is overex-
pressed in ovarian clear cell carcinoma, the sequence
229KKMRRNR235 is essential for its nuclear localisation in trans-
duced cell lines. The HNF1bDBD was identified to interact with a
spectrum of Importin-a isoforms by pull-down assays and we have
further characterised the interaction between the putative NLS
peptide and Importin-a using complementary biophysical tech-
niques. Furthermore, we have determined the crystal structure of
Importin-a in complex with the HNF1b NLS peptide to 2.4 Å reso-
lution. This information should facilitate the development of com-
pounds that target the nuclear import of the transcription factor.
We have shown that HNF1b interacts strongly with Importin-a5
and selectively targeting this Importin-HNF1b interaction may
open new avenues for the development of targeted therapeutics
for ovarian clear cell carcinoma along the lines discussed by
Stelma et al. (2016).
3.5. Data deposition
Co-ordinates and structure factors for the structure of the
HNF1b peptides bound to Importin-a have been deposited at the
Protein Data Bank (PDB) with accession code 5K9S.
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